Core Insights - Windtree Therapeutics, Inc. announced a presentation by Dr. Alexandre Mebazaa on istaroxime, highlighting data from the Phase 2b SEISMiC B study for early cardiogenic shock due to heart failure [1][4] - Istaroxime is a first-in-class investigational therapy aimed at improving cardiac function and increasing blood pressure, showing a favorable safety profile [3][5] Company Overview - Windtree Therapeutics focuses on innovative therapies for critical conditions, with a portfolio that includes istaroxime, which is currently in Phase 2 trials for acute heart failure and cardiogenic shock [6] - The company also develops preclinical SERCA2a activators for heart failure and aPKCi inhibitors for oncology applications, alongside a licensing business model [6] Clinical Data and Efficacy - Istaroxime has demonstrated significant improvements in systolic blood pressure and cardiac output without increasing heart rate or causing clinically significant arrhythmias [4][5] - The therapy has been studied in four positive Phase 2 trials, indicating its potential effectiveness in treating early cardiogenic shock [3][5]
Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials Conference